What is Haematologic Technologies?
Haematologic Technologies, headquartered in Essex Junction, Vermont, is a prominent provider of specialized research reagents, custom blood collection tubes, and comprehensive protein biochemistry services. The company's expertise spans assay development, validation, and GMP release and stability testing. With a core focus on protein biochemistry and blood coagulation, Haematologic Technologies offers contract research and development services, including custom protein purification, modification, and GMP-compliant testing. Their product catalog features over 150 high-quality blood coagulation products, such as proteins, antibodies, inhibitors, substrates, deficient plasmas, and custom IVD/POC reagents, alongside bespoke blood and specimen collection tubes.
How much funding has Haematologic Technologies raised?
Haematologic Technologies has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Haematologic Technologies
PPP
Public-Private Partnership
What's next for Haematologic Technologies?
The substantial large-scale late-stage funding indicates that Haematologic Technologies is poised for significant scaling and market penetration. This strategic capital infusion is likely to fuel further research and development, enhance manufacturing capabilities, and expand its global reach. The company's emphasis on specialized reagents and services within the critical fields of blood coagulation and diagnostics positions it for continued innovation and leadership in the life sciences industry. Future growth may involve strategic partnerships or acquisitions to broaden its service offerings and solidify its market dominance.
See full Haematologic Technologies company page
